LEXX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 11:33):

Stats
Today's Volume	82 401.00
Average Volume	477 270
Market Cap	42.39M
EPS	$0 ( 2024-04-12 )
Next earnings date	( $-0.130 ) 2024-07-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.91
ATR14	$0.0240 (0.73%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-14	Carle Vanessa	Sell	2 500	Stock Options
2024-05-14	Carle Vanessa	Buy	2 500	common shares
2024-04-26	Carle Vanessa	Buy	10 000	Stock Options
2024-04-26	Turkel Catherine C.	Buy	5 000	Stock Options
2024-04-26	Baxter Nicholas W	Buy	5 000	Stock Options

INSIDER POWER
11.08
Last 99 transactions
Buy: 3 496 310 \| Sell: 1 994 235

Volume Correlation

Long: 0.06 (neutral)

Short: -0.87 (strong negative)

Signal:(53.205) Neutral

Lexaria Bioscience Corp. Correlation

10 Most Positive Correlations
KNSL	0.873
AIHS	0.871
LBC	0.87
PASG	0.863
VTYX	0.862
POWL	0.862
OCUL	0.862
SLN	0.859
LMAT	0.856
CLBT	0.855

10 Most Negative Correlations
DSPC	-0.859
DCRC	-0.853
GSM	-0.832
MDRX	-0.826
DPRO	-0.818
SRNGW	-0.807
XEL	-0.806
SGLB	-0.804
SSRM	-0.804
ATSG	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lexaria Bioscience Corp. Correlation - Currency/Commodity

0.17
( neutral )

-0.37
( neutral )

0.00
( neutral )

0.41
( neutral )

0.00
( neutral )

-0.02
( neutral )

Lexaria Bioscience Corp. Financials

Annual	2023
Revenue:	$226 208
Gross Profit:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2023
Revenue:	$226 208
Gross Profit:	$194 708 (86.07 %)
EPS:	$-1.010

FY	2022
Revenue:	$255 397
Gross Profit:	$183 556 (71.87 %)
EPS:	$-1.240

FY	2021
Revenue:	$722 738
Gross Profit:	$547 392 (75.74 %)
EPS:	$-0.950

Financial Reports:

No articles found.

Lexaria Bioscience Corp. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Lexaria Bioscience Corp.

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.